Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
10. Dezember 2024 09:55 ET
|
Profound Medical Corp.
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public...
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
06. Dezember 2024 09:04 ET
|
Profound Medical Corp.
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical...
Profound Medical Announces Proposed Public Offering of Common Shares
05. Dezember 2024 16:48 ET
|
Profound Medical Corp.
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp....
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
02. Dezember 2024 07:30 ET
|
Profound Medical Corp.
– Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – ...
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
26. November 2024 07:45 ET
|
Profound Medical Corp.
TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
12. November 2024 08:00 ET
|
Profound Medical Corp.
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Third Quarter 2024 Financial Results
07. November 2024 16:05 ET
|
Profound Medical Corp.
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
04. November 2024 06:55 ET
|
Profound Medical Corp.
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective...
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
17. Oktober 2024 16:30 ET
|
Profound Medical Corp.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
16. Oktober 2024 16:15 ET
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...